AR117219A1 - Formulaciones en cápsulas, método de preparación - Google Patents

Formulaciones en cápsulas, método de preparación

Info

Publication number
AR117219A1
AR117219A1 ARP190103505A ARP190103505A AR117219A1 AR 117219 A1 AR117219 A1 AR 117219A1 AR P190103505 A ARP190103505 A AR P190103505A AR P190103505 A ARP190103505 A AR P190103505A AR 117219 A1 AR117219 A1 AR 117219A1
Authority
AR
Argentina
Prior art keywords
compound
formula
solid solution
solution capsule
capsules
Prior art date
Application number
ARP190103505A
Other languages
English (en)
Spanish (es)
Inventor
Jay P Powers
Manmohan Reddy Leleti
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117219(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AR117219A1 publication Critical patent/AR117219A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP190103505A 2018-11-30 2019-11-29 Formulaciones en cápsulas, método de preparación AR117219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
AR117219A1 true AR117219A1 (es) 2021-07-21

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103505A AR117219A1 (es) 2018-11-30 2019-11-29 Formulaciones en cápsulas, método de preparación

Country Status (31)

Country Link
US (4) US20200170957A1 (cg-RX-API-DMAC7.html)
EP (3) EP3886820B8 (cg-RX-API-DMAC7.html)
JP (1) JP7342124B2 (cg-RX-API-DMAC7.html)
KR (1) KR102586747B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164403A (cg-RX-API-DMAC7.html)
AR (1) AR117219A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019389031B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120999C (cg-RX-API-DMAC7.html)
CL (1) CL2021001389A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126079T1 (cg-RX-API-DMAC7.html)
DK (2) DK4233850T3 (cg-RX-API-DMAC7.html)
ES (2) ES2943492T3 (cg-RX-API-DMAC7.html)
FI (2) FI3886820T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241735T1 (cg-RX-API-DMAC7.html)
HU (2) HUE069633T2 (cg-RX-API-DMAC7.html)
IL (1) IL283450B2 (cg-RX-API-DMAC7.html)
LT (2) LT4233850T (cg-RX-API-DMAC7.html)
MA (2) MA54318B1 (cg-RX-API-DMAC7.html)
MD (2) MD3886820T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006242A (cg-RX-API-DMAC7.html)
NZ (1) NZ776554A (cg-RX-API-DMAC7.html)
PL (2) PL4233850T3 (cg-RX-API-DMAC7.html)
PT (2) PT4233850T (cg-RX-API-DMAC7.html)
RS (2) RS66362B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105572UA (cg-RX-API-DMAC7.html)
SI (2) SI4233850T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400521T1 (cg-RX-API-DMAC7.html)
TW (1) TWI827745B (cg-RX-API-DMAC7.html)
WO (1) WO2020112961A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103820B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN116635075A (zh) * 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病
JP2025516701A (ja) * 2022-05-19 2025-05-30 ダウ グローバル テクノロジーズ エルエルシー Bcsクラスiiの薬物の改良された可溶化のためのpegベースのインターポリマー錯体の使用
US20250164505A1 (en) * 2023-11-20 2025-05-22 Qatar Foundation For Education, Science And Community Development Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
MX363066B (es) * 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
EP2659090B1 (en) 2010-12-27 2017-08-23 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
CN106102716A (zh) 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
JP6898229B6 (ja) 2014-09-29 2021-07-28 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト製造における方法及び中間体
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
DK3411400T3 (da) 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス,インコーポレイティド ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂

Also Published As

Publication number Publication date
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
BR112021010285A2 (pt) 2021-08-17
MA62992B1 (fr) 2025-01-31
DK3886820T3 (da) 2023-05-15
IL283450A (en) 2021-07-29
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
FI4233850T3 (fi) 2024-12-30
JP2022510304A (ja) 2022-01-26
SI4233850T1 (sl) 2025-03-31
CL2021001389A1 (es) 2021-12-24
LT3886820T (lt) 2023-06-12
US20240299306A1 (en) 2024-09-12
MX2021006242A (es) 2021-09-10
EP3886820B8 (en) 2023-05-17
RS66362B1 (sr) 2025-01-31
FI3886820T3 (fi) 2023-05-25
HRP20241735T1 (hr) 2025-02-28
ZA202103820B (en) 2026-03-25
EP3886820A1 (en) 2021-10-06
AU2019389031B2 (en) 2023-06-15
EP4233850B1 (en) 2024-10-02
AU2019389031A1 (en) 2021-06-17
ES2998858T3 (en) 2025-02-21
PT4233850T (pt) 2024-12-30
NZ776554A (en) 2024-12-20
SI3886820T1 (sl) 2023-07-31
KR102586747B1 (ko) 2023-10-06
DK4233850T3 (da) 2025-01-02
HUE069633T2 (hu) 2025-04-28
EP4487915A2 (en) 2025-01-08
CA3120999C (en) 2025-04-01
ES2943492T3 (es) 2023-06-13
PL4233850T3 (pl) 2025-03-17
WO2020112961A1 (en) 2020-06-04
CN113164403A (zh) 2021-07-23
EP4487915A3 (en) 2025-03-19
US20220233453A1 (en) 2022-07-28
SMT202300153T1 (it) 2023-09-06
IL283450B2 (en) 2024-06-01
MD4233850T2 (ro) 2025-02-28
TWI827745B (zh) 2024-01-01
CY1126079T1 (el) 2023-11-15
PT3886820T (pt) 2023-05-24
JP7342124B2 (ja) 2023-09-11
KR20210098489A (ko) 2021-08-10
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
HRP20230551T1 (hr) 2023-08-18
SG11202105572UA (en) 2021-06-29
US20250375385A1 (en) 2025-12-11
MD3886820T2 (ro) 2023-07-31
EP4233850A2 (en) 2023-08-30
EP3886820B1 (en) 2023-04-12
IL283450B1 (en) 2024-02-01
TW202038952A (zh) 2020-11-01
EP3886820A4 (en) 2022-08-24
MA54318B1 (fr) 2023-08-31
MA54318A (fr) 2021-10-06
RS64250B1 (sr) 2023-06-30
CA3120999A1 (en) 2020-06-04
US20200170957A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
CL2020000747A1 (es) Formulaciones de niraparib.
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
NI201700135A (es) Derivados de ciclohexano sustituido con amido
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
CR20220018A (es) Derivados de imidazol [4,5-c] piridina como agonistas de receptores tipo toll
MX2016009063A (es) Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
PE20190347A1 (es) Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
MX2019004576A (es) Composiciones farmaceuticas.
PE20181333A1 (es) Derivados de indano y su uso en terapias
AR121966A1 (es) Composiciones sólidas que contienen amina, amina protonada o compuestos de amonio cuaternario
AR099870A1 (es) Derivados de 4,5-dihidro-1h-pirazol-3-carboximidamida que contienen grupos azufre, método para prepararlos, y composición farmacéutica que los comprende
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina